Mark Schoenebaum, Evercore ISI analyst, discusses his thoughts on the biotech rally. » Read More
We are putting cash back to work, said Ron Muhlenkamp, portfolio manager at The Muhlenkamp Fund, and Jeff Mortimer, CIO of Charles Schwab Investment Management.
How will male General Motors retirees get their motor runnin'? Do they start paying for their impotence drugs out of their own pocket? Because apparently, under the new deal the company won't pick up the tab anymore.
Consumers may be saving more and spending less, but big pharma is on a shopping spree. And I'm not talking about the really big deals including Roche buying Genentech, Pfizer buying Wyeth and Merck buying Schering-Plough. I'm talking about the two deals that have been done in less than a week between major drug companies and baby biotechs specializing in oncology.
One year after urging regulators to guide Lehman Brothers toward a recapitalization and recognition of its losses, hedge fund manager David Einhorn is making more potentially prescient speeches—this time about ratings agencies and gold.
Plus, Cramer explains why First Niagara is just the type of bank that investors want right now.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Hewlett Packard reported earnings after the bell yesterday, and met analyst expectations. All 30 Dow stocks have now reported -- here is a summary of how the season stacked up.
Kirk Kerkorian and Warren Buffett are two more of the world’s richest investors who have just revealed how they’re gaming stocks!
Following are the day’s biggest winners and losers. Find out why shares of CME Group and Philip Morris popped while Ford and Citigroup dropped.
Market Trivia Question: Which four stocks have more than doubled since the market’s current low back in March? As investors debate whether the market rally still "has legs," four Dow components have more than doubled since the Dow hit a multi-year low.
Pfizer Chairman and CEO Jeff Kindler last year repeatedly said big deals in big pharma don't work. But, he added, he'd never say never. And sure enough, this year Kindler's buying Wyeth.
This takes the prize for the most dangerously optimistic acronym for a clinical trial. But MADIT (pronounced "made it") made it. Some folks with a lot of chutzpah at Guidant, now owned by Boston Scientific, apparently came up with the name for their big studies on implantable cardio defibrillators.
Stocks rose on Thursday, snapping a two-day losing streak, as investors gave techs another go and Wal-Mart hit its earnings target. However, some economic reports that missed expectations curbed gains. Experts weighed in on the markets, the commercial real estate, and more...
Stocks lost more than 2% Wednesday as bank shares continued to struggle and retail sales unexpectedly fell for a second straight month.
A gloomy sales report dragged down investor sentiment on Wednesday sending the S&P 500 to its third straight day of declines.
Stocks declined Wednesday as bank shares continued to struggle and retail sales unexpectedly fell for a second straight month. A brief reprieve after the business-inventories report and comments from President Obama fizzled.
Over the past few months I've blogged a couple of times about the public service announcement Pfizer produced in the UK to discourage guys from buying and taking counterfeit Viagra.
What does it say when a drugmaker hires a Goldman Sachs investment banker as its next Chief Financial Officer? That's the question I'm asking after Novartis announced that it's tapped a managing director of investment banking at Goldman Sachs, Jonathan Symonds, as its CFO apprentice.
Stocks pared their losses Wednesday after a report showed business inventories shrunk at a slower pace and remarks from President Obama on health-care reform. Still, stocks remained under pressure as bank shares continued to struggle and retail sales unexpectedly fell for a second straight month.
With stocks rallying for over 2 months now, dividend yields continue to fall back to Earth. The average dividend yield of the Dow 30 has fallen nearly 30% since the rally began in early March. See how the 30 companies in the Dow compare.